BACKGROUND: Interleukin-23 (IL-23) is a pro-inflammatory cytokine that is thought to be central to the development of autoimmune diseases. This study was conducted to determine whether or not the serum concentration of IL-23 is elevated in patients with rheumatoid arthritis (RA), and to determine the relationship between the IL-23 level and disease activity in RA patients. METHODS: Serum samples were obtained from 59 patients with RA and 30 healthy controls. The clinical parameters of disease activity were determined, including the 28-joint disease activity score (DAS28), C-reactive protein (CRP), rheumatoid factor (RF) levels, and the degree of bony erosions based on X-rays. The levels of IL-23 and IL-17 were determined by enzyme-linked immunosorbent assay (ELISA). The correlations between the serum levels of IL-23 and disease activity parameters of patients with RA were determined. RESULTS: The serum IL-23 level was significantly elevated in patients with RA compared to healthy controls. The serum IL-23 levels in the RA patients correlated with IL-17 and CRP levels, and the DAS28. The levels of IL-23 based on X-ray classification phase I, II, III, and IV were gradually elevated in RA patients. CONCLUSIONS: The levels of serum IL-23 in RA patients were higher than in healthy controls. Thus, elevated serum IL-23 levels may be useful markers to detect active RA. In addition, IL-23 is involved in disease progression and bony erosions in patients with RA.
BACKGROUND:Interleukin-23 (IL-23) is a pro-inflammatory cytokine that is thought to be central to the development of autoimmune diseases. This study was conducted to determine whether or not the serum concentration of IL-23 is elevated in patients with rheumatoid arthritis (RA), and to determine the relationship between the IL-23 level and disease activity in RApatients. METHODS: Serum samples were obtained from 59 patients with RA and 30 healthy controls. The clinical parameters of disease activity were determined, including the 28-joint disease activity score (DAS28), C-reactive protein (CRP), rheumatoid factor (RF) levels, and the degree of bony erosions based on X-rays. The levels of IL-23 and IL-17 were determined by enzyme-linked immunosorbent assay (ELISA). The correlations between the serum levels of IL-23 and disease activity parameters of patients with RA were determined. RESULTS: The serum IL-23 level was significantly elevated in patients with RA compared to healthy controls. The serum IL-23 levels in the RApatients correlated with IL-17 and CRP levels, and the DAS28. The levels of IL-23 based on X-ray classification phase I, II, III, and IV were gradually elevated in RApatients. CONCLUSIONS: The levels of serum IL-23 in RApatients were higher than in healthy controls. Thus, elevated serum IL-23 levels may be useful markers to detect active RA. In addition, IL-23 is involved in disease progression and bony erosions in patients with RA.
Authors: K Köck; W J Pan; J M Gow; M J Horner; J P Gibbs; A Colbert; T J Goletz; K J Newhall; W A Rees; Y Sun; Y Zhang; J C O'Neill; A N Umble-Romero; S P Prokop; C D Krill; L Som; S A Buntich; M W Trimble; W H Tsuji; J E Towne Journal: Br J Pharmacol Date: 2014-12-15 Impact factor: 8.739
Authors: Mariángeles Noto Llana; Sebastián Hernán Sarnacki; María del Rosario Aya Castañeda; María Isabel Bernal; Mónica Nancy Giacomodonato; María Cristina Cerquetti Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240